NCT05705258View on ClinicalTrials.gov

A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)

RecruitingOBSERVATIONAL
Enrollment

75

Participants

Timeline

Start Date

March 27, 2023

Primary Completion Date

April 1, 2026

Study Completion Date

March 30, 2027

Conditions
Retinopathy of PrematurityNewbornsInfants
Interventions
DRUG

Aflibercept (Eylea, BAY86-5321)

Treatment with Intravitreal (IVT)-AFL must be made by the treating ophthalmologist

Trial Locations (1)

Unknown

RECRUITING

Many locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT05705258 - A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity) | Biotech Hunter | Biotech Hunter